Print this page
-
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon -
A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.
Protocol: 071807Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon
- 1
- 2